RNAZ - TransCode Therapeutics Reports Prolonged Survival when Glioblastoma is Treated with Its Lead Candidate TTX-MC138 in Murine Models

2023-10-26 08:31:18 ET

DENVER, Colo., Oct 26, 2023 ( www.247marketnews.com )- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) reported, this morning, improved survival in murine models bearing human glioblastoma multiforme (GBM) tumors treated with its lead therapeutic candidate, TTX-MC138. In this study, mice implanted with human GBM tumors treated with TTX-MC138 survived significantly longer than those in the control group.

TransCode Therapeutics is trading at $0.43, up $0.06 (+15.90%), on 561.6K premarket shares traded.

Its 52-week range is $0.301 to $23.40. It hit a new 52-week low on Monday and is trying to reverse that downtrend. Its next key inflection point is 52-cents.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our …

The post TransCode Therapeutics Reports Prolonged Survival when Glioblastoma is Treated with Its Lead Candidate, TTX-MC138, in Murine Models appeared first on 24/7 Market News .

For further details see: